Infant RSV hospitalizations increased in second season after nirsevimab immunization
A two year study revealed that infant hospital admissions for respiratory syncytial virus were higher during the second season than during the initial protection period following nirsevimab immunization.
FTMQ Health, written by our newsroom0 views
Infant hospital admissions for respiratory syncytial virus increased during the second season of life following nirsevimab immunization, Bioengineer.org reported. The findings come from a two year follow up study published in the journal Frontiers in Public Health. [1]
The research used a self-controlled case series methodology to evaluate hospitalization rates. In the adjusted self-controlled analysis, hospitalization rates during the second respiratory syncytial virus season were 7.99 times higher than during the initial effectiveness period of the antibody. The study reported a 95 percent confidence interval ranging from 5.80 to 11.02. [1]
Nirsevimab is a long acting monoclonal antibody created to protect infants against respiratory syncytial virus. Respiratory syncytial virus, also known as human orthopneumovirus, is a single-stranded RNA virus that causes infections of the human respiratory tract. [1][2]
Immunization functions by exposing the immune system to foreign molecules so the body learns to protect itself against infectious agents. The process relies on the adaptive immune system, including T cells and B cells, to develop immunological memory. [4]
In short
- Infant RSV hospitalization rates were 7.99 times higher in the second season following nirsevimab immunization than during the initial protection period.
- The 95 percent confidence interval for the second season hospitalization rate increase spanned from 5.80 to 11.02.
- Nirsevimab is a long-acting monoclonal antibody designed to protect infants against respiratory syncytial virus.
- The two-year follow-up study was published in Frontiers in Public Health using a self-controlled case series design.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]RSV Hospitalizations Rose in Second Year Following Infant Nirsevimab ImmunizationBioengineer.org, 19h ago (the report this story comes from)
Background
- [2]Respiratory syncytial virus on Wikipedia
- [3]COVID-19 pandemic in the United States on Wikipedia
- [4]Immunization on Wikipedia
- [5]Royal College of Pharmacy ends sponsorship deal with Israeli drug firm FTMQ Health, 44d ago
Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- International trial tests oral bacterial lysate to prevent infant wheezeMedical Science, 9d ago
- Residential radon exposure linked to higher heart failure risk in womenTop Stories, 13d ago
- Oregon hospital financial aid mandate faces pushback after initial successHealth Care, 31d ago
- Saudi study finds low disease rates in premarital screeningPublic Health, 23d ago
- Current local respiratory illnesses are unlikely to be influenza UVA epidemiologist saysPublic Health, 36d ago
More in Public Health
- Iran ministry panel rejects universal childhood hepatitis A vaccination16h ago
- Frequent social media use linked to anxiety in Egyptian university staff1d ago
- Review links air pollution and socioeconomic status to Parkinson's disease risk6d ago
- Changes in surveillance rules altered reported Finnish syphilis trends and demographics7d ago
- Mathematical framework evaluates fairness in public health epidemic models10d ago
- Pancreatic cancer deaths co-recorded with cardiovascular disease increased nationwide10d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.